Daunorubicin or idarubicin

Phase 3Small molecule

Daunorubicin or idarubicin is one of 53 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaActive, not recruiting

Leukemia, Myeloid, AcuteActive, not recruiting

FLT3-Mutated Acute Myeloid LeukemiaActive, not recruiting

Acute Myeloid LeukemiaPhase 3

Active, not recruiting

Leukemia, Myeloid, AcutePhase 1

Active, not recruiting

FLT3-Mutated Acute Myeloid LeukemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Neupogen

EEastern Cooperative Oncology Group

Phase 3

31 2

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

31 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

28 4

Novantrone

EMD Serono

Phase 3

19 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 6

Tibsovo

SServier

Phase 3

8 7

Dalalone

CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Phase 3

1 8

Campath

GGenzyme, a Sanofi Company

Salvage Chemotherapy

1 10

Recombinant FLT3 Ligand

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Leukemia, Myeloid, Acute

NCT05453903

Q2 2029

Phase 2Active, not recruiting

FLT3-Mutated Acute Myeloid Leukemia

NCT03591510

Q4 2033

Phase 3Not yet recruiting

Acute Myeloid Leukemia

NCT07223814

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Not yet recruiting·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 3·NCT07223814·875 enrolled

FLT3-mutated Acute Myeloid Leukemia1 trial

A Phase II, Open-label, Single Arm Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (PKC412) Combined With Standard Chemotherapy and as a Single Agent Post-consolidation Therapy in Children With Untreated FLT3-mutated AML

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT03591510·22 enrolled

Leukemia, Myeloid, Acute1 trial

A Phase 1b Study of Bleximenib in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT05453903·196 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Daunorubicin or idarubicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Daunorubicin or idarubicin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Daunorubicin or idarubicin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

Daunorubicin or idarubicin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2029

Q4 2033

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

FLT3-mutated Acute Myeloid Leukemia1 trial

Leukemia, Myeloid, Acute1 trial

References

Drug Info

Quick Facts

Related News